Is Now the Time to Go All-In On Novavax Stock?

On June 14, Novavax (NASDAQ: NVAX) announced that its recombinant nanoparticle coronavirus vaccine, NVX-CoV2373, had demonstrated 93% overall efficacy against coronavirus variants in phase 3 trials -- and that number shot up to 100% for severe or critical COVID-19. The vaccine candidate was also well-tolerated, with serious adverse events spread out equally between placebo and treatment groups.

Unfortunately, shareholders have been acting in a "buy the rumor, sell the news" sort of manner. Shares fell about 10% after Novavax published the results. As of now, the company is pretty undervalued relative to its vaccine production capacity and potential commercialization. Should investors put all their eggs in one basket for this stock?

Image source: Getty Images.

Source Fool.com